CAJ | 학술논문

2012年9月国家中医药管理局正式委托世界中医药学会联合会组织开展“中医药临床研究伦理审查平台评估”（CAP）。通过对已完成评估的20家医疗卫生机构的伦理审查平台情况进行综合分析，结合当前美国的伦理监管体系，论述我国自主评估品牌CAP的重要特点，“以评促建”和“持续改进”的实践与受益，以及大力推进CAP评估的重要意义。
2012년9월국가중의약관리국정식위탁세계중의약학회연합회조직개전“중의약림상연구윤리심사평태평고”（CAP）。통과대이완성평고적20가의료위생궤구적윤리심사평태정황진행종합분석，결합당전미국적윤리감관체계，논술아국자주평고품패CAP적중요특점，“이평촉건”화“지속개진”적실천여수익，이급대력추진CAP평고적중요의의。
In September 2012, the "Assessment for Ethics Review of Traditional Chinese Medicine (TCM) Re-search with Human Participants" (named CAP, Chinese medicine assessment human research protection system) was officially commissioned to the World Federation of Chinese Medicine Societies to organize by the State Ad-ministration of TCM. Through the assessment of 20 medical institutions, a comprehensive analysis on ethical re-view platform was conducted. Combined with current regulatory system of ethics in the U.S., this article discussed independent assessment on important CAP features of local brands, the practice and benefit of "construction pro-motion based on assessment" and "continuous improvement," as well as the importance of vigorously promote CAP assessment .